FDA approves pembrolizumab plus axitinib for advanced RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved pembrolizumab plus axitinib (Keytruda) for the first-line treatment of patients with advanced renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login